Phase II trial of VP-16, bleomycin, and cisplatin in patients with advanced nonsquamous cell head and neck neoplasms

E. T. Creagan; A. J. Schutt; R. L. Richardson; D. J. Schaid

doi:10.1097/00000421-199308000-00003

Phase II trial of VP-16, bleomycin, and cisplatin in patients with advanced nonsquamous cell head and neck neoplasms

E. T. Creagan, A. J. Schutt, R. L. Richardson, D. J. Schaid

Quantitative Health Sciences

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

We observed a 45% response rate from the combination of VP-16, bleomycin, and cisplatin among 20 patients with nonsquamous cell head and neck cancer. The regressions were partial and typically occurred within 1 to 2 months of commencing treatment. The median response duration for responding patients was 3 months. Median survival of responders was 8 months, similar to that of all study participants. Gastrointestinal and hematologic sequelae were predictable and manageable. This regimen may provide some transient palliation for selected patients with these neoplasms, but no substantive impact on survival.

Original language	English (US)
Pages (from-to)	291-294
Number of pages	4
Journal	American Journal of Clinical Oncology: Cancer Clinical Trials
Volume	16
Issue number	4
DOIs	https://doi.org/10.1097/00000421-199308000-00003
State	Published - 1993

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1097/00000421-199308000-00003

Cite this

@article{bfa75ffdd9c1463e98b590e74fb11453,

title = "Phase II trial of VP-16, bleomycin, and cisplatin in patients with advanced nonsquamous cell head and neck neoplasms",

abstract = "We observed a 45% response rate from the combination of VP-16, bleomycin, and cisplatin among 20 patients with nonsquamous cell head and neck cancer. The regressions were partial and typically occurred within 1 to 2 months of commencing treatment. The median response duration for responding patients was 3 months. Median survival of responders was 8 months, similar to that of all study participants. Gastrointestinal and hematologic sequelae were predictable and manageable. This regimen may provide some transient palliation for selected patients with these neoplasms, but no substantive impact on survival.",

author = "Creagan, {E. T.} and Schutt, {A. J.} and Richardson, {R. L.} and Schaid, {D. J.}",

year = "1993",

doi = "10.1097/00000421-199308000-00003",

language = "English (US)",

volume = "16",

pages = "291--294",

journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",

issn = "0277-3732",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Phase II trial of VP-16, bleomycin, and cisplatin in patients with advanced nonsquamous cell head and neck neoplasms

AU - Creagan, E. T.

AU - Schutt, A. J.

AU - Richardson, R. L.

AU - Schaid, D. J.

PY - 1993

Y1 - 1993

N2 - We observed a 45% response rate from the combination of VP-16, bleomycin, and cisplatin among 20 patients with nonsquamous cell head and neck cancer. The regressions were partial and typically occurred within 1 to 2 months of commencing treatment. The median response duration for responding patients was 3 months. Median survival of responders was 8 months, similar to that of all study participants. Gastrointestinal and hematologic sequelae were predictable and manageable. This regimen may provide some transient palliation for selected patients with these neoplasms, but no substantive impact on survival.

AB - We observed a 45% response rate from the combination of VP-16, bleomycin, and cisplatin among 20 patients with nonsquamous cell head and neck cancer. The regressions were partial and typically occurred within 1 to 2 months of commencing treatment. The median response duration for responding patients was 3 months. Median survival of responders was 8 months, similar to that of all study participants. Gastrointestinal and hematologic sequelae were predictable and manageable. This regimen may provide some transient palliation for selected patients with these neoplasms, but no substantive impact on survival.

UR - http://www.scopus.com/inward/record.url?scp=0027218623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027218623&partnerID=8YFLogxK

U2 - 10.1097/00000421-199308000-00003

DO - 10.1097/00000421-199308000-00003

M3 - Article

C2 - 7687089

AN - SCOPUS:0027218623

SN - 0277-3732

VL - 16

SP - 291

EP - 294

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

IS - 4

ER -

Phase II trial of VP-16, bleomycin, and cisplatin in patients with advanced nonsquamous cell head and neck neoplasms

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this